Decera Clinical Education Infectious Disease Podcast

In this episode, Martin Rios discusses how pre-exposure prophylaxis (PrEP) persistence depends on healthcare professional knowledge, including:Their own experiences with the various PrEP providers they have seenThe relief that has come with seeing PrEP providers who are supportive and knowledgeable about the different PrEP optionsThe challenges that have come with seeing PrEP providers who are unwilling to prescribe PrEP altogether or who will prescribe PrEP when asked but are not knowledgeable about the optionsFaculty: Martin RiosPrEP User and AdvocatePhiladelphia, PennsylvaniaLink to full program:https://bit.ly/3ZlICsL Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this episode, Meredith Clement, MD, and Whitney C. Irie, MSW, PhD, discuss key considerations for pre-exposure prophylaxis (PrEP) uptake in cisgender women, including: How to incorporate conversations on PrEP during a short clinic visit Helpful resources about PrEP to share with patientsLeveraging clinic staff to improve PrEP uptake and persistence Available data on on-demand PrEPApproach to discussing PrEP contraindications and adverse events with patientsConsiderations for PrEP in pregnant persons or those wanting to conceive The importance of inclusiveness in PrEP marketing Key barriers limiting PrEP uptake in cisgender women (eg, stigma, risk perception)Interventions to improve PrEP uptakeFacultyMeredith Clement, MDAssociate Professor Infectious Diseases Louisiana State University Health Sciences CenterNew Orleans, Louisiana Whitney C. Irie, MSW, PhDAssistant ProfessorDepartment of Social WorkBoston CollegeBrighton, Massachusetts Link to full program: https://bit.ly/3PZGYdR Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this episode, Helen Y. Chu, MD, MPH, shares updates on RSV seasonality, including: Surveillance limitations due to the testing availability in adultsCurrent 2023/2024 season trends, including predictions for other respiratory viruses (eg, influenza, SARS-CoV-2)Considerations for RSV administrationRSV vaccine coadministration with influenza and COVID-19 vaccinesFaculty: Helen Y. Chu, MD, MPHAssociate Professor of MedicineDivision of Allergy & Infectious DiseasesUniversity of Washington School of MedicineSeattle, WashingtonLink to full program: https://bit.ly/3nb25xeLink to downloadable slides: https://bit.ly/3TsXym5 Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this episode, Rick Zimmerman, MD, MPH, FAAFP, discusses RSV vaccines in older adults, including: Breakthroughs in RSV vaccine developmentRSV vaccine snapshot in older adultsFDA-approved RSV vaccines for older adultsCDC evidence to recommendations framework for vaccinesRSV burden in older populationsBenefits and harms of RSV vaccinationRSV vaccine efficacy and safety in older adultsCDC Advisory Committee Immunization Practices recommendations for RSV vaccines in older adultsPopulations at high risk for severe RSV diseaseVaccination considerations based on the upcoming RSV seasonFaculty:Richard Zimmerman, MD, MPH, FAAFPProfessorDepartment of Family Medicine and Clinical Epidemiology University of PittsburghPittsburgh, PennsylvaniaContent based on an online CME program supported by an independent educational grant from GlaxoSmithKline.Link to full program: https://bit.ly/49YBZ4rLink to downloadable slides: https://bit.ly/3GocjRe Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this episode, Angela Branche, MD; Pamela Rockwell, DO, FAAFP; and Richard Zimmerman, MD, MPH, FAAFP, discuss the clinical presentation of RSV in older adults and available diagnostic tests for RSV, including: Comparison of RSV clinical symptoms to influenza and COVID-19, including differentiating symptoms at infection onsetRSV disease progression RSV diagnostic approaches How RSV diagnosis of adults may differ from diagnosis of childrenClinical considerations for RSV testingHow to improve RSV awareness among patientsProgram Director:Pamela Rockwell, DO, FAAFPProfessorFamily MedicineUniversity of Michigan Medical SchoolAnn Arbor, MichiganFaculty:Angela Branche, MDAssociate Professor of MedicineDivision of Infectious DiseasesDepartment of MedicineUniversity of RochesterRochester, New YorkRichard Zimmerman, MD, MPH, FAAFPProfessorDepartment of Family Medicine and Clinical Epidemiology University of PittsburghPittsburgh, PennsylvaniaContent based on an online CME program supported by an independent educational grant from GlaxoSmithKline.Link to full program:https://bit.ly/49YBZ4rLink to downloadable slides: https://bit.ly/3GocjRe Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this episode, Samantha V. Hill, MD, MPH, and Eunice E. Radcliff, MD, discuss key considerations for PrEP uptake in adolescents, including: Advice on talking with parents about the importance of adolescents having alone time with their healthcare professionalsMaintaining confidentiality when someone is on their parents’ insuranceStrategies to increase awareness, uptake, engagement, and persistence on PrEP among adolescentsHaving discussions about HIV prevention and PrEP along with the HPV vaccine, STI testing, or contraceptionFacultySamantha V. Hill, MD, MPHAssistant ProfessorDivision of General PediatricsSection on Adolescent HealthDepartment of PediatricsEmory UniversityAtlanta, GeorgiaEunice E. Radcliff, MDAssistant Professor General PediatricsEmory University School of MedicineAtlanta, GeorgiaLink to full program: https://bit.ly/3PZGYdR Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this episode, Jean-Michel Molina, MD, PhD, discusses the data and recommendations for considering on-demand PrEP as a strategy to support PrEP persistence and engagement for men who have sex with men, including:Nondaily PrEP options recommended for cisgender menData from the ANRS IPERGAY study evaluating on-demand FTC/TDF vs placebo in men who have sex with menReal-world data on the effectiveness of on-demand PrEPConsiderations for on-demand FTC/TDF in people with renal dysfunctionData on hypertension and statin initiation risk with FTC/TAF PrEPData on weight gain with the different PrEP optionsFacultyJean-Michel Molina, MD, PhDProfessor of Infectious DiseasesUniversity of Paris CitéHead of the Department of Infectious DiseasesHospital Saint-Louis and LariboisièreParis, FranceFollow along with the slideshttps://bit.ly/47VGZVLLink to full program:https://bit.ly/3ZlICsL Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Should quantitative HBsAg testing be used routinely in clinical practice for patients living with chronic hepatitis B?In this episode, Tatyana Kushner, MD, MSCE, discusses the role of quantitative hepatitis B surface antigen testing in people living with chronic hepatitis B, including:Determination of inactive carrier statusPrediction of liver fibrosis/cirrhosisPrediction of hepatocellular carcinoma developmentMonitoring response to treatment, including future HBV treatments in the development pipelinePrediction of HBsAg lossJoining her for the panel discussion are Ira M. Jacobson, MD, and Paul Y. Kwo, MD.Presenters:Ira M. Jacobson, MDProfessor of MedicineDirector of HepatologyNYU Langone HealthNew York, New YorkTatyana Kushner, MD, MSCEAssociate ProfessorDivision of Liver DiseasesIcahn School of Medicine at Mount SinaiNew York, New YorkPaul Y. Kwo, MDProfessor of Medicine Director of Hepatology Stanford University School of MedicinePalo Alto, CaliforniaLink to the full program: https://bit.ly/3R1PMi4Link to the slides: https://bit.ly/3N5Fpsm Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Are we treating HBV early enough? Is it time to move the goalposts regarding the timing of treatment initiation? What are the potential benefits of earlier treatment?To answer these questions, Ira M. Jacobson, MD, leads a panel discussion with Tatyana Kushner, MD, MSCE, and Paul Y. Kwo, MD, exploring which patients with HBV we should be treating, including a focus on:Guideline-based treatment recommendations and their limitationsData describing the relationship between viral suppression and HBV DNA integrationMore expansive indications for HBV treatment based on virologic considerationsPresenters:Ira M. Jacobson, MDProfessor of MedicineDirector of HepatologyNYU Langone HealthNew York, New YorkTatyana Kushner, MD, MSCEAssociate ProfessorDivision of Liver DiseasesIcahn School of Medicine at Mount SinaiNew York, New YorkPaul Y. Kwo, MDProfessor of Medicine Director of Hepatology Stanford University School of MedicinePalo Alto, CaliforniaLink to the full program: https://bit.ly/3R1PMi4Link to the slides: https://bit.ly/3N5Fpsm Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this episode, Angela Branche, MD; Pamela Rockwell, DO, FAAFP; and Rick Zimmerman, MD, MPH, FAAFP, discuss the burden of RSV in older adults, including:RSV burden throughout lifeRSV seasonality in the United StatesComparative burden and incidence of RSV and influenza in adults aged 65 years or olderCardiopulmonary hospitalizations of long-term care facility residents with influenza and/or RSVRisk factors for severe RSV (eg, hospitalization, mortality) in older adultsRSV incidence by presence of underlying medical conditionsRSV awareness among healthcare professionals and patients Program Director:Pamela Rockwell, DO, FAAFPProfessorFamily MedicineUniversity of Michigan Medical SchoolAnn Arbor, MichiganFaculty:Angela Branche, MDAssociate Professor of MedicineDivision of Infectious DiseasesDepartment of MedicineUniversity of RochesterRochester, New YorkRichard Zimmerman, MD, MPH, FAAFPProfessorDepartment of Family Medicine and Clinical Epidemiology University of PittsburghPittsburgh, PennsylvaniaContent based on an online CME program supported by an independent educational grant from GlaxoSmithKline.Link to full program: https://bit.ly/49YBZ4rLink to downloadable slides: https://bit.ly/3GocjRe Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this episode, Beatriz Grinsztejn, MD, PhD, discusses the data and recommendations for addressing social determinants as a strategy to support PrEP persistence and engagement for transgender women, including: HIV prevalence among transgender womenData on the PrEP cascade from the PrEParadas study of daily FTC/TDF among transgender womenData from the ImPrEP Study on early loss to follow-up, adherence, long-term engagement, and HIV incidence among transgender womenBarriers to PrEP uptake and adherence for transgender womenDrug–drug interactions between PrEP and feminizing hormone therapyIncreasing PrEP uptake and retention with peer health navigation for transgender womenFacultyBeatriz Grinsztejn, MD, PhDDirectorHIV/STI Clinical Research LaboratoryInstituto Nacional de Infectologia Evandro Chagas-FiocruzRio de Janeiro, BrazilIAS President-ElectLink to full program:https://bit.ly/3ZlICsL Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this accredited podcast episode, Dr Christina Madison and Dr Mary Bridgeman provide practical strategies for implementing RSV vaccination into practice, including: Educating older adults on RSV vaccinesProviding effective, evidence-based recommendationsShared decision-makingIdentifying and addressing vaccine hesitancyProactive strategies in vaccinating for RSVPredicting and overcoming barriers to RSV vaccinationPresenters:Mary Barna Bridgeman, PharmD, BCPS, BCGP, FASCP, FCCP, FNAPClinical ProfessorErnest Mario School of PharmacyRutgers, The State University of New JerseyPiscataway, New JerseyInternal Medicine PharmacistRobert Wood Johnson University HospitalNew Brunswick, New JerseyChristina M. Madison, PharmD, FCCP, AAHIVPClinical PharmacistFounder and CEO, The Public Health Pharmacist, PLLCAdjunct Associate Professor of Pharmacy PracticeRoseman University of Health SciencesCollege of PharmacyHenderson, NevadaOther program activities: Frontiers in RSV Prevention for Older Adults: Developments, Recommendations, and the Pharmacist’s Role https://bit.ly/49GUv1gLink to CME: Claim Credit – https://bit.ly/3uoY7VH[After selecting the “Continue to Post Test” button:]To receive continuing education credit, submit your posttest answers no later than the expiration of this activity. Select the best answer to each question. When you have completed all the questions, press the "Continue" button at the bottom. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this accredited podcast episode, Dr Christina Madison and Dr Mary Bridgeman discuss the latest practical strategies for preventing RSV infection in older adults, including: Role of basic public health precautionsAvailable and emerging vaccines Mechanisms of action, therapeutic targets, and pharmacologyEfficacy and safety dataFDA approval status and ACIP recommendations Presenters: Mary Barna Bridgeman, PharmD, BCPS, BCGP, FASCP, FCCP, FNAPClinical ProfessorErnest Mario School of PharmacyRutgers, The State University of New JerseyPiscataway, New JerseyInternal Medicine PharmacistRobert Wood Johnson University HospitalNew Brunswick, New JerseyChristina M. Madison, PharmD, FCCP, AAHIVP Clinical PharmacistFounder and CEO, The Public Health Pharmacist, PLLCAdjunct Associate Professor of Pharmacy PracticeRoseman University of Health SciencesCollege of PharmacyHenderson, NevadaOther program activities: • Frontiers in RSV Prevention for Older Adults: Developments, Recommendations, and the Pharmacist’s Role Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this accredited podcast episode, Dr Mary Bridgeman discusses the most important things for pharmacists across all settings to know about RSV infections in patients 60 years of age or older, including: Incidence and prevalence of RSV in older adults, including hospitalization, mortality, epidemiologySeasonalityClinical manifestationsRisk factors for severe outcomesVulnerable groups and comorbiditiesPresenter:Mary Barna Bridgeman, PharmD, BCPS, BCGP, FASCP, FCCP, FNAPClinical ProfessorErnest Mario School of PharmacyRutgers, The State University of New JerseyPiscataway, New JerseyInternal Medicine PharmacistRobert Wood Johnson University HospitalNew Brunswick, New JerseyOther program activities: Frontiers in RSV Prevention for Older Adults: Developments, Recommendations, and the Pharmacist’s Role https://bit.ly/49GUv1gLink to CME: Claim Credit – https://bit.ly/47GtNnK[After selecting the “Continue to Post Test” button:]To receive continuing education credit, submit your posttest answers no later than the expiration of this activity. Select the best answer to each question. When you have completed all the questions, press the "Continue" button at the bottom. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this episode, Aniruddha (Anu) Hazra, MD, and Ofole Mgbako, MD, discuss key considerations for PrEP uptake in transgender individuals and racial and ethnic minority men who have sex with men, including: Data on drug–drug interactions between PrEP options and gender-affirming hormone therapyContributing factors to inequities in PrEP uptake for Black and Latino individualsData on FTC/TAF PrEP for transgender individualsHow to decide whether to do an oral lead-in before starting injectable cabotegravir PrEPTime to effectiveness after starting PrEP PrEP resources available for transgender communities, especially regarding stigmaIntegration of PrEP with gender-affirming hormone therapyStrategies to increase PrEP uptake, specifically in the southCounseling patients on drug–drug interactions, adverse events, and transmission risk when starting PrEPInvolving PrEP navigators in the care of people receiving PrEPSupporting PrEP adherence and retention in careThe use of DoxyPEP in transgender individuals receiving PrEPFacultyAniruddha (Anu) Hazra, MDAssistant Professor, Section of Infectious Disease and Global HealthDirector, Infectious Diseases Fellowship ProgramMedical Director, UCM Sexual Wellness ClinicDirector of STI Services, Chicago Center of HIV EliminationDepartment of MedicineUniversity of ChicagoChicago, IllinoisOfole Mgbako, MDAssistant Professor of Medicine and Population Health Section Chief of Infectious DiseaseBellevue HospitalClinical Pillar Lead, NYU Institute for Excellence in Health EquityNYU Grossman School of MedicineNYU Langone HealthNew York, New YorkLink to full program: https://bit.ly/3PZGYdR Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this episode,Emily Heil, PharmD, MS, BCIDP, AAHIVP; Laila Woc-Colburn, MD; and Trevor Van Schooneveld, MD, FSHEA, FACP, discuss their approach to managing infections caused by NDM-producing Enterobacterales, including: Ambler classification of β-lactamasesMechanisms of resistance2023 IDSA guidance recommendationsThe latest clinical data by antimicrobial regimen:Ceftazidime/avibactam and aztreonamCefiderocolInvestigational aztreonam/avibactamClinical case of NDM-producing E. coli with pan-β-lactam resistanceProgram Director:Trevor Van Schooneveld, MD, FSHEA, FACP Professor, Division of Infectious DiseasesProgram Director, Infectious Diseases FellowshipMedical Director, Antimicrobial Stewardship ProgramUniversity of Nebraska Medical CenterOmaha, NebraskaFaculty:Emily Heil, PharmD, MS, BCIDP, AAHIVPAssociate ProfessorDepartment of PharmacyUniversity of Maryland School of PharmacyID Clinical Pharmacy SpecialistUniversity of Maryland Medical CenterBaltimore, MarylandLaila Woc-Colburn, MDAssociate ProfessorDivision of Infectious DiseasesEmory University School of Medicine Atlanta, GeorgiaContent based on a CME program supported by an educational grant from Merck & Co., Inc., Rahway, NJ, USA.Follow along with a downloadable slideset at: https://bit.ly/476v2wILink to full program:https://bit.ly/40HyvPy Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this episode, Emily Heil, PharmD, MS, BCIDP, AAHIVP; Laila Woc-Colburn, MD; and Trevor Van Schooneveld, MD, FSHEA, FACP, discuss their approach to managing infections involving Pseudomonas aeruginosa with difficult-to-treat resistance, including: Mechanisms of β-lactam resistanceEffect of resistance mechanism on susceptibility to antipseudomonal agent2023 IDSA guidance recommendations Activity against newer antipseudomonal β-lactams in the United StatesThe latest clinical data by antimicrobial regimen: - Ceftolozane/tazobactam - Ceftazidime/avibactam - Imipenem/cilastatin/relebactam - CefiderocolApplying antimicrobial stewardship principlesProgram Director:Trevor Van Schooneveld, MD, FSHEA, FACP Professor, Division of Infectious DiseasesProgram Director, Infectious Diseases FellowshipMedical Director, Antimicrobial Stewardship ProgramUniversity of Nebraska Medical CenterOmaha, NebraskaFaculty:Emily Heil, PharmD, MS, BCIDP, AAHIVPAssociate ProfessorDepartment of PharmacyUniversity of Maryland School of PharmacyID Clinical Pharmacy SpecialistUniversity of Maryland Medical Center|Baltimore, MarylandLaila Woc-Colburn, MDAssociate ProfessorDivision of Infectious DiseasesEmory University School of Medicine Atlanta, GeorgiaContent based on a CME program supported by an educational grant from Merck & Co., Inc., Rahway, NJ, USA.Follow along with a downloadable slideset at: https://clinicaloptions.com/CE-CME/infectious-disease/cmv-prevention-in-sot-recipients/26139Link to full program: https://bit.ly/40HyvPy Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this episode, Emily Heil, PharmD, MS, BCIDP, AAHIVP; Laila Woc-Colburn, MD; and Trevor Van Schooneveld, MD, FSHEA, FACP, discuss their approach to managing infections involving carbapenem-resistant Acinetobacter baumannii (CRAB), including: Mechanisms for β-lactam resistanceAdditional resistance mechanisms and virulence factors2023 IDSA guidance recommendations for moderate to severe CRAB infectionsThe latest clinical data by antimicrobial therapy/regimen:SulbactamMeropenem and colistinCarbapenem, sulbactam, and polymyxin BTetracyclinesCefiderocolSulbactam/durlobactam and carbapenems Program Director:Trevor Van Schooneveld, MD, FSHEA, FACP Professor, Division of Infectious DiseasesProgram Director, Infectious Diseases FellowshipMedical Director, Antimicrobial Stewardship ProgramUniversity of Nebraska Medical CenterOmaha, NebraskaFaculty:Emily Heil, PharmD, MS, BCIDP, AAHIVPAssociate ProfessorDepartment of PharmacyUniversity of Maryland School of PharmacyID Clinical Pharmacy SpecialistUniversity of Maryland Medical CenterBaltimore, MarylandLaila Woc-Colburn, MDAssociate ProfessorDivision of Infectious DiseasesEmory University School of Medicine Atlanta, GeorgiaContent based on a CME program supported by an educational grant from Merck & Co., Inc., Rahway, NJ, USA.Follow along with a downloadable slideset at: https://bit.ly/476v2wILink to full program: https://bit.ly/40Mmicz Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this second of 3 episodes, global HIV experts and advocates discuss how HIV care can better meet the diverse needs of people living with HIV as new treatment strategies emerge and continue to evolve, including:How the emergence of long-acting injectable HIV treatment has been a game-changer for many people living with HIVEmerging strategies that are expanding the application of long-acting ART to address unmet treatment needsPotential for future innovations in ART that are hoped will further address unmet needs and preferences of people living with HIVFaculty: Ann Avery, MDProfessor of MedicineCase Western Reserve UniversityDivision of Infectious DiseasesMetroHealth Medical CenterCleveland, OhioJennifer Blanchette, PhDIndependent ContractorClinical Care OptionsColorado, United StatesIsolde Butler, MD, MPHChief Medical OfficerCrescentCareNew Orleans, LouisianaMonica Gandhi, MD, MPHProfessor of MedicineDivision of HIV, Infectious Diseases, and Global MedicineDirector, Center for AIDS Research (CFAR)Medical Director, Ward 86 HIV ClinicUniversity of California, San Francisco (UCSF)San Francisco, CaliforniaMarissa GonzalezChair Community Advisory Board The Well ProjectAngelina Namiba Founder Member4M Network of Mentor MothersLondon, United KingdomChloe Orkin, MBChB, FRCP, MDProfessor of Infection and InequitiesFaculty of Medicine and DentistryQueen Mary University of LondonBlizard InstituteBarts Health NHS TrustLondon, United KingdomLink to full program:https://bit.ly/3QFwv7nLinks to programs discussed in the episode:www.4mmm.org Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this episode, global PrEP experts and advocates discuss how current PrEP regimens represent a revolutionary step forward in enabling many individuals to avoid HIV acquisition, including: How PrEP has empowered people to take control of their sexual lives, revolutionized people’s sexual experiences, and, for some, improved their experiences with healthcare in generalThe extraordinary progress that has been made in New South Wales and specifically in inner Sydney toward HIV transmission elimination and the role of PrEP in the prevention of new HIV infectionsThe importance of having PrEP options, including on-demand options and long-acting formulations, available to different populations who could benefit to see progress toward HIV transmission elimination globallyFaculty: Jessica L. Adams, PharmD, AAHIVEScientific Director, Infectious DiseasesClinical Care OptionsNew York, United StatesLinda-Gail Bekker, MBChB, DCH, DTM&H, FCP(SA), PhDProfessor and DirectorThe Desmond Tutu HIV CentreUniversity of Cape TownSouth AfricaChief Executive OfficerThe Desmond Tutu Health FoundationCape Town, South AfricaKenyon R. FarrowPrEP AdvocateVice President of PolicyPoint Source YouthContributing EditorTheBody.comOhio, United StatesBeatriz Grinsztejn, MD, PhDDirectorSTI/AIDS Clinical Research LaboratoryInstituto Nacional de Infectologia Evandro Chagas-FiocruzRio de Janeiro, BrazilAndrew Grulich, MBBS, PhDScientia ProfessorHead, HIV Epidemiology and Prevention ProgramThe Kirby InstituteUniversity of New South Wales, SydneyNew South Wales, AustraliaJean-Michel Molina, MD, PhDProfessor of Infectious DiseasesUniversity of Paris CitéHead of the Department of Infectious DiseasesHospital Saint-Louis and LariboisièreParis, FranceBrittany Williams, PhDPrEP AdvocateAssistant Professor of Higher Education and Student Affairs AdministrationDepartment of Education University of Vermont Vermont, United StatesLink to full program: https://bit.ly/3FbPBey Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this episode, global PrEP experts and advocates discuss barriers that have prevented the full potential of today’s PrEP regimens from being delivered, how those barriers might be overcome, and how the next generation of PrEP modalities may address unmet needs, including: How access and implementation of PrEP have limited its benefit and led to disparities in uptake among racial and ethnic groups in the United States and among key populations globallyThe challenges of adherence to PrEP for healthy individuals who are required to consistently take medication and engage with the healthcare system when they aren’t sickThe potential for longer-acting PrEP modalities and a greater number of PrEP options for individuals in the future to expand PrEP uptake and adherence with equitable global accessFaculty: Jessica L. Adams, PharmD, AAHIVEScientific Director, Infectious DiseasesClinical Care OptionsNew York, United StatesLinda-Gail Bekker, MBChB, DCH, DTM&H, FCP(SA), PhDProfessor and DirectorThe Desmond Tutu HIV CentreUniversity of Cape TownSouth AfricaChief Executive OfficerThe Desmond Tutu Health FoundationCape Town, South AfricaKenyon R. FarrowPrEP AdvocateVice President of PolicyPoint Source YouthContributing EditorTheBody.comOhio, United StatesBeatriz Grinsztejn, MD, PhDDirectorSTI/AIDS Clinical Research LaboratoryInstituto Nacional de Infectologia Evandro Chagas-FiocruzRio de Janeiro, BrazilBrittany Williams, PhDPrEP AdvocateAssistant Professor of Higher Education and Student Affairs AdministrationDepartment of Education University of Vermont Vermont, United StatesLink to full program: https://bit.ly/3FbPBey Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this episode, Lillian Abbo, MD, MBA, FIDSA, discusses appropriate antimicrobial selection for managing uncomplicated UTIs, including:Balancing discrepancies in available guidelines Individualizing antimicrobial selection based on patient characteristics and local resistance patterns Incorporating tools, like antibiograms, into daily practice Being a good steward of currently available antimicrobial agents Planning ahead for emerging therapies for uncomplicated UTIsPresenter:Lillian Abbo, MD, MBA, FIDSAAssociate Chief Medical Officer Infectious DiseasesJackson Health SystemProfessor of Clinical Infectious DiseasesUniversity of Miami Miller School of MedicineMiami Transplant InstituteMiami, FloridaFind other program activities here: “Uncomplicated” Doesn’t Mean Easy: Recognizing the Burden and Preventing Treatment Failure of Uncomplicated UTIsSlides on “Uncomplicated” Doesn’t Mean Easy: Recognizing the Burden and Preventing Treatment Failure of Uncomplicated UTIsPodcast 1: Burden on Uncomplicated Urinary Tract InfectionsPodcast 3: When Things Get Complicated: Managing uUTIs in Acute CareClinicalThought: Not Always an Easy Task: Antimicrobial Stewardship for Uncomplicated UTIs Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this episode, Lilly C. Lee, MD, SM, FACEP, FAAEM, discusses the best practices in management of uUTI in the emergency department, including:Patient triageDiagnostic stewardshipInterdisciplinary careStrategies to overcome treatment barriersPresenter:Lilly C. Lee, MD, SM, FACEP, FAAEMChief of Emergency MedicineJackson Memorial HospitalFlorida Poison Information CenterRoxcy Bolton Rape Treatment CenterAffiliated Assistant Professor of SurgeryDeWitt Daughtry Family Department of SurgeryLeonard M. Miller School of MedicineUniversity of MiamiMiami, FloridaFind other program activities here: “Uncomplicated” Doesn’t Mean Easy: Recognizing the Burden and Preventing Treatment Failure of Uncomplicated UTIsSlides on “Uncomplicated” Doesn’t Mean Easy: Recognizing the Burden and Preventing Treatment Failure of Uncomplicated UTIsPodcast 1: Burden on Uncomplicated Urinary Tract InfectionsPodcast 2: Updates in Antimicrobial Selection for uUTIsClinicalThought: When Care Gets Complicated: Uncomplicated UTI Management in Acute Care Settings Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this episode, Richard Colgan, MD, discusses the burden of uncomplicated UTIs (uUTIs) and best practices in their management, including:Accurate diagnosis and classificationRisk factors for uUTIs and treatment failureBurdens of uUTIs on patientsInnovations in care, including self-diagnosis and virtual managementThe importance of avoiding screening and management of asymptomatic bacteriuria in most patientsWe will also hear from a patient who details the impact of uUTI on her quality of life. Presenter:Richard Colgan, MD​Executive Vice ChairProfessor of Family and Community MedicineUniversity of Maryland School of MedicineBaltimore, MarylandFind other program activities here: “Uncomplicated” Doesn’t Mean Easy: Recognizing the Burden and Preventing Treatment Failure of Uncomplicated UTIsSlides on “Uncomplicated” Doesn’t Mean Easy: Recognizing the Burden and Preventing Treatment Failure of Uncomplicated UTIsPodcast 2: Updates in Antimicrobial Selection for uUTIsPodcast 3: When Things Get Complicated: Managing uUTIs in Acute CareClinicalThought: Uncomplicated but Not Insignificant: The Burden of Uncomplicated UTIs Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this episode, Atul Humar, MD, FRCP(C); Hannah Imlay, MD, MS; and Raymund Razonable, MD, discuss cytomegalovirus (CMV) management strategies in solid organ transplantation recipients, including:Evaluation of current data on CMV prevention in liver transplant recipientsPractical considerations for switching an institution’s antiviral therapy of choice for primary prophylaxisBarrier of resistance to antiviral therapiesFactors to consider when deciding CMV treatment durationUse of lymphocyte count to assess CMV cell–mediated immunityProgram Director:Atul Humar, MD, FRCP(C)Professor of MedicineUniversity of Toronto Director, Ajmera Transplant CentreUniversity Health NetworkR. Fraser Elliott Chair in TransplantationDirector University of Toronto Transplant InstituteToronto, Ontario, CanadaFaculty:Hannah Imlay, MD, MSAssistant Professor of MedicineDepartment of Internal Medicine, Division of Infectious DiseasesUniversity of Utah Salt Lake City, UtahRaymund Razonable, MDProfessor of MedicineProgram Director, Infectious Diseases FellowshipVice Chair, Division of Infectious DiseasesMayo ClinicRochester, Minnesota Content based on a CME program supported by an educational grant from Merck & Co., Inc., Rahway, NJ, USA.Follow along with a downloadable slideset at: https://bit.ly/476v2wILink to full program: https://bit.ly/47lNK2K Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this episode, Hannah Imlay, MD, MS, discusses cytomegalovirus (CMV) prevention strategies in solid organ transplantation (SOT) recipients including:Strategies for preventing CMV in SOTInternational guideline recommendations for CMV prevention strategies by organ typeAntivirals used for CMV preventionComparison of preemptive therapy vs prophylaxis for CMV prevention in liver transplant recipientsComparison of letermovir vs valganciclovir for CMV prophylaxis in kidney transplant recipientsUse of CMV cell–mediated immunity monitoring for primary prophylaxisMonitoring CMV viral loads, including limitations to quantitative nucleic acid testingFuture prevention approachesFaculty:Hannah Imlay, MD, MSAssistant Professor of MedicineDepartment of Internal Medicine, Division of Infectious DiseasesUniversity of Utah Salt Lake City, UtahContent based on a CME program supported by an educational grant from Merck & Co., Inc., Rahway, NJ, USA.Follow along with a downloadable slideset at: https://bit.ly/476v2wILink to full program: https://bit.ly/47lNK2K Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this episode, Raymund Razonable, MD, discusses cytomegalovirus (CMV) management strategies beyond primary prophylaxis in solid organ transplantation recipients including:CMV treatment goals CMV treatment and monitoring recommendationsRole of secondary prophylaxisUse of CMV cell–mediated immunity (CMI) monitoring for CMV relapse riskUse of CMV CMI for secondary prophylaxis Proposed use of CMV CMI monitoring for secondary prophylaxisIncidence and outcomes with antiviral resistance Risk factors for CMV resistanceWhen to suspect antiviral resistance Testing for antiviral resistance using genotypic assaysOutcomes in patients with ganciclovir-resistant vs ganciclovir-susceptible virusTreatment recommendations for resistant/refractory CMVEfficacy and safety of maribavir vs investigator-assigned therapy for resistant/refractory CMV infections from the phase III SOLTICE studyTreatment algorithm for resistant/refractory CMV Adjunctive, investigational, and off-label treatment options for resistant/refractory CMV Faculty:Raymund Razonable, MDProfessor of MedicineProgram Director, Infectious Diseases FellowshipVice Chair, Division of Infectious DiseasesMayo ClinicRochester, Minnesota Content based on a CME program supported by an educational grant from Merck & Co., Inc., Rahway, NJ, USA.Follow along with a downloadable slideset at: https://bit.ly/476v2wILink to full program: https://bit.ly/47lNK2K Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Arthur Kim, MD, and Renslow Sherer, MD, discuss how new data on COVID-19 vaccines and treatments may affect practice, including:Real-world data on COVID-19 outcomesCOVID-19 prevention: current and emerging conceptsCOVID-19 therapeutics: new clinical trial and real-world dataPresenters:Arthur Kim, MDAssociate Professor of MedicineHarvard Medical SchoolDivision of Infectious DiseasesMassachusetts General HospitalBoston, MassachusettsRenslow Sherer, MDDirectorInternational HIV Training CenterProfessor of MedicineSection of Infectious Diseases and Global HealthDepartment of MedicineUniversity of ChicagoChicago, IllinoisFollow along with the slides at:https://bit.ly/40DFjhvLink to full program: https://bit.ly/3FI8HJx Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this first of 3 episodes, global HIV experts and advocates discuss how innovative models of care are minimizing barriers to HIV care engagement to improve uptake by key underserved populations, including:How peer support programs empower people to combat stigma, become more educated about treatment, and be engaged participants in their HIV careStrategies for addressing potential unmet mental healthcare needs among people living with HIVApproaches to reengage people with HIV who transit through county jail systemsHow integrated care strategies and wrap-around services can overcome some of the barriers to care that are associated with social determinants of healthKey considerations when providing HIV care for migrant and refugee populations Faculty:Ann Avery, MDProfessor of MedicineCase Western Reserve UniversityDivision of Infectious DiseasesMetroHealth Medical CenterCleveland, OhioJennifer Blanchette, PhDIndependent ContractorClinical Care OptionsColorado, United StatesIsolde Butler, MD, MPHChief Medical OfficerCrescentCareNew Orleans, LouisianaMonica Gandhi, MD, MPHProfessor of MedicineDivision of HIV, Infectious Diseases, and Global MedicineDirector, Center for AIDS Research (CFAR)Medical Director, Ward 86 HIV ClinicUniversity of California, San Francisco (UCSF)San Francisco, CaliforniaMarissa GonzalezChairCommunity Advisory BoardThe Well ProjectAngelina NamibaFounder Member4M Network of Mentor MothersLondon, United KingdomChloe Orkin, MBChB, FRCP, MDProfessor of Infection and InequitiesFaculty of Medicine and DentistryQueen Mary University of LondonBlizard InstituteBarts Health NHS TrustLondon, United KingdomMiłosz Parczewski, MD, PhDProfessor of MedicineDepartment HeadConsultant in Infectious DiseasesDepartment of Infectious, Tropical Diseases and Acquired ImmunodeficiencyPomeranian Medical UniversitySzczecin, PolandLink to full program:https://bit.ly/3QFwv7nLinks to programs discussed in the episode:https://4mmm.org/https://positivepeers.org/ Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this episode, Shannon Kasperbauer, MD, discusses guideline-based treatment recommendations for people with M. abscessus, including a discussion of:Macrolide resistancePredictors for disease progression2020 NTM guideline recommended treatment optionsEmerging therapiesWe will also hear from a patient who describes how she remained adherent during long courses of treatment for M. abscessus.Finally, we hear Dr Kasperbauer discuss a patient case with her colleagues, Charles L. Daley, MD, and Pamela J. McShane, MD.Presenters:Charles L. Daley, MD​Professor of Medicine​Division of Mycobacterial and Respiratory Infections ​National Jewish Health​Denver, Colorado​Shannon Kasperbauer, MD​Associate Professor of Medicine​Division of Mycobacterial and Respiratory Infections​National Jewish Health​Denver, Colorado​Pamela J. McShane, MD​Professor of Medicine​Division of Pulmonary and ​Critical Care Medicine​The University of Texas Health Science Center at Tyler​Tyler, TexasLink to program page: https://bit.ly/3QzJo2BLink to downloadable slides: https://bit.ly/3Qh8T7G Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this episode, Charles L. Daley, MD, discusses guideline-based treatment recommendations for nontuberculous mycobacterial (NTM) lung disease, including treatment regimens for:Mycobacterium avium complexM. kansasiiM. xenopiWe will also hear from a patient who describes the use of airway clearance devices and a patient who describes his typical NTM treatment course.Finally, we hear Dr. Daley discuss a patient case with his colleagues, Shannon Kasperbauer, MD, and Pamela J. McShane, MD.Presenters:Charles L. Daley, MD​Professor of Medicine​Division of Mycobacterial and Respiratory Infections ​National Jewish Health​Denver, Colorado​Shannon Kasperbauer, MD​Associate Professor of Medicine​Division of Mycobacterial and Respiratory Infections​National Jewish Health​Denver, Colorado​Pamela J. McShane, MD​Professor of Medicine​Division of Pulmonary and ​Critical Care Medicine​The University of Texas Health Science Center at Tyler​Tyler, TexasLink to program page: https://bit.ly/3QzJo2BLink to downloadable slides: https://bit.ly/3Qh8T7G Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this episode, Pamela J. McShane, MD, describes the 3 pillars for nontuberculous mycobacterial (NTM) lung disease diagnosis:Clinical symptomsRadiographic evidenceMicrobiologic dataWe will also hear from a patient who details his diagnostic journey and will hear Dr. McShane discuss an illustrative clinical case.Presenter: Pamela J. McShane, MD Professor of Medicine Division of Pulmonary and Critical Care Medicine The University of Texas Health Science Center at Tyler Tyler, Texas Link to program page: https://bit.ly/3QzJo2BLink to downloadable slides: https://bit.ly/3Qh8T7G Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this episode, David Alain Wohl, MD, discusses key considerations to PrEP barriers in cisgender women, including:Prevalence of PrEP use in the USBarriers to PrEP uptake PrEP efficacy based on adherenceInterventions to support PrEP adherenceRecommended PrEP regimens, including considerations for use in pregnancy and breastfeeding Presenter: David Alain Wohl, MDProfessor of MedicineSchool of MedicineSite Leader, Global Infectious Diseases Clinical Trials UnitUniversity of North Carolina at Chapel Hill Chapel Hill, North Carolina Content based on an online CME program supported by an independent educational grant from ViiV Healthcare. Link to full program: https://bit.ly/3ZpM6uuFollow along with the slides: https://bit.ly/3LyGgBj Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this podcast, experts Sarah M. Wood, MD, MS, and Errol L. Fields, MD, PhD, MPH, discuss some of the challenges and concerns clinicians face when prescribing PrEP to adolescents. The faculty addresses the potential for adverse effects from PrEP, including the potential for renal impairment, decreased bone density, and whether PrEP can interfere with hormone therapy for gender-affirming care. They review the data behind these concerns and emphasize that the vast majority of adverse effects caused by PrEP are mild and reversible.The experts also examine common barriers that adolescents face when attempting to initiate and adhere to PrEP, such as insurance coverage and confidentiality. Dr Fields and Dr Woods discuss strategies for overcoming these barriers and retaining adolescents on PrEP, including how to navigate tricky conversations with both patients and parents or within communities that may stigmatize PrEP and HIV.Sarah M. Woods, MD, MSAssistant Professor of PediatricsDivision of Adolescent MedicineUniversity of Pennsylvania Perelman School of MedicineChildren’s Hospital of PhiladelphiaPhiladelphia, PennsylvaniaErrol L. Fields, MD, PhD, MPHAssociate Professor of PediatricsDivision of Adolescent/Young Adult MedicineDepartment of PediatricsJohns Hopkins School of MedicineBaltimore, MarylandContent based on an online CME program supported by independent educational grants from Gilead Sciences Inc. and ViiV Healthcare.Link to full program: https://bit.ly/3PZGYdR Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this episode, we hear from 2 people living with HIV: Melanie Reese from the United States and Marc Thompson from the United Kingdom. Both Melanie and Marc have done important work in the HIV field as patient advocates. Today, they will be discussing their experiences in accessing and navigating their own HIV care, with a focus on some of the barriers that can complicate and even block a person's journey across the HIV care continuum. In reviewing these challenges, Marc and Melanie share their insights on key strategies that can help to facilitate HIV care for patients, making the experience more straightforward and minimizing the impact that HIV has on their daily lives. Presenters:Melanie ReeseSubject Matter Expert, Older Women Living and Aging with HIV, HIV North America Health Resources and Services Administration HIV/AIDS BureauExecutive Director, Older Women Embracing LifeBoard Secretary, International Community of Women Living with HIVBaltimore, MarylandMarc ThompsonDirector, The Love TankCo-founder, PrepsterLondon, EnglandContent based on an online CME/CPE/CE program supported by an independent educational grant from Gilead Sciences, Inc. Link to full program:https://bit.ly/3Pas4zn Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this podcast, expert Rasika Karnik, MD, MS, discusses how to manage the health risks posed by COVID-19 infection and long COVID in individuals with metabolic syndrome or obesity.Dr Karnik discusses the interplay between COVID-19 outcomes, obesity/metabolic syndrome, and social determinants of health and delves into detail on how to address and mitigate these social determinants of health in a high-risk population.Presenters:Rasika Karnik, MD, MSAssistant ProfessorDivision of Primary Care, Department of Internal MedicineUniversity of ChicagoChicago, IllinoisContent based on an online CME program supported by independent educational grants from Pfizer.Link to full program: https://bit.ly/46yuChS Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this podcast, experts Donna Ryan, MD, and Renslow Sherer, MD, discuss how to manage the health risks posed by COVID-19 infection and long COVID in individuals with metabolic syndrome or obesity.First, Dr Ryan presents an overview of the relationship between COVID-19 and weight, including the mechanisms of how obesity may drive COVID-19 disease and how COVID-19 may in turn worsen obesity, through both immunologic and social or societal drivers.Dr Ryan also discusses the relationship between obesity and the risk for long COVID.In his segment, Dr Sherer discusses COVID-19 vaccination and antiviral therapy within the context of obesity and metabolic syndrome. Dr Sherer also delves into detail on how obesity-related risk factors or comorbidities may affect treatment decisions and presents strategies on individualizing treatment, including in patients with long COVID.This episode includes results from several reviews and meta-analyses examining the relationship between vaccination, as well as an observational study investigating the impact of nirmatrelvir/ritonavir therapy on long COVID in vaccinated patients.Presenters:Donna Ryan, MDProfessor Emerita Pennington Biomedical Research Center New Orleans, Louisiana Renslow Sherer, MDDirector of the International HIV Training Center Professor of MedicineInfectious Diseases and Global Health Department of Medicine University of Chicago Department of Medicine Chicago, IllinoisContent based on an online CME program supported by independent educational grants from Pfizer.Link to full program:https://bit.ly/46yuChS Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this episode, Oni Blackstock, MD, MHS, and Whitney Irie, MSW, PhD, discuss key considerations for PrEP uptake in cisgender women, including: Ways to perform a nonintimidating sexual history How to incorporate conversations on PrEP during a short clinic visit Discussing adverse events associated with PrEP options with patientsConsiderations for PrEP in women wanting to conceive How patients can navigate obtaining PrEP in areas with limited healthcare resources Guideline recommendation updates on PrEP eligibility Use of wrap-around services Interventions to improve PrEP access (eg, telehealth, nurse-led PrEP)FacultyOni Blackstock, MD, MHSFounder & Executive DirectorHealth JusticeNew York, New YorkWhitney Irie, MSW, PhDAssistant ProfessorDepartment of Social WorkBoston CollegeBrighton, Massachusetts Link to full program: https://bit.ly/3PZGYdR Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this episode, Roger Bedimo, MD, MS, FACP, discusses key considerations to PrEP barriers in adolescents, including: New HIV diagnoses in the United StatesAdherence barriersHealthcare professional barriersConsent laws for minors to receive sexually transmitted infection diagnosis and treatment services Interventions to support PrEP adherence Presenter: Roger Bedimo, MD, MS, FACPProfessor of MedicineDivision of Infectious DiseasesUniversity of Texas UT Southwestern Medical CenterSection ChiefDepartment of Internal MedicineVA North Texas Health Care SystemDallas, TexasContent based on an online CME program supported by an independent educational grant from ViiV Healthcare.Link to full program:https://bit.ly/3ZpM6uuFollow along with the slides:https://bit.ly/3LyGgBj Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this episode, Brooke Bates, PharmD, BCPS, AAHIVP, and Neha Sheth Pandit, PharmD, AAHIVP, BCPS, discuss the most clinically relevant studies on HIV adverse events presented at IAS 2023, including: REPRIEVE study of pitavastatin for cardiovascular prevention in people living with HIV at low to moderate cardiovascular riskData on weight change with switch from integrase inhibitor–based ART to doravirine/islatravir in the P017 and P018 studiesDEFINE study evaluating weight change after a switch to DRV/COBI/FTC/TAF in people living with HIV who experienced weight gain with integrase inhibitor–based ARTFaculty: Brooke Bates, PharmD, BCPS, AAHIVPSpecialty Pharmacy Clinical Manager Pediatric HIV Clinical PharmacistIndiana University HealthIndianapolis, IndianaNeha Sheth Pandit, PharmD, AAHIVP, BCPSProfessorVice Chair for Research and ScholarshipDepartment of Practice, Sciences, and Health Outcomes ResearchSchool of PharmacyUniversity of Maryland Clinical PharmacistTHRIVE ProgramBaltimore, MarylandLink to full program: https://bit.ly/3ZjSFhg Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this episode, Tony Brown, MPH, discusses the importance of effective patient‒provider communication in supporting PrEP persistence including: His own experience with PrEP and reasons for fluctuations in adherence over the years The importance of open, honest, and judgement-free conversations about sexual health Engaging patients in conversations about PrEP effectiveness, adverse effects, and changing life circumstances Working together to find the most effective PrEP option for each individual patient that will help them to persist on PrEP long term Faculty: Tony Brown, MPH PrEP User and Advocate Doctoral Candidate Health Services Policy and Management University of South Carolina Columbia, South Carolina Link to full program: https://bit.ly/3ZlICsL Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this episode, Nikos Dedes, Jeff Taylor, and Bernadette Sharp—people living with HIV—discuss how switching to long-acting ART has affected their quality of life. They are joined by 2 healthcare professionals—Iskandar Azwa,MBChB, MRCP, and Beng Eu, MBBS—who provide insights on how they assess and document health-related quality of life for their patients. The discussion focuses on personal experiences with how LA ART has improved health-related quality of life, including:Avoidance of drug–drug interactionsImproved confidentiality Decreased stigmaPresenters:Iskandar Azwa, MBChB, MRCPAssociate ProfessorInfectious DiseasesFaculty of MedicineUniversity of MalayaKuala Lumpur, MalaysiaNikos DedesPositive VoiceAthens, GreeceBeng Eu, MBBSDoctorPrahran Market Clinic Melbourne, Victoria, AustraliaBernadette SharpAdvocateJeff TaylorExecutive DirectorHIV+Aging Research ProjectPalm Springs, CaliforniaContent based on an online CME program supported by an independent educational grant from ViiV Healthcare.ViiV Healthcare was not involved in the development of content or selection of faculty for this educational activity.Link to downloadable slides: https://bit.ly/488WwT7Link to full program: bit.ly/3EwEnRJ Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this episode, Jill Blumenthal, MD, MAS, and Kenric B. Ware, PharmD, MBA, AAHIVP, answer questions about HIV PrEP including:Considerations for selecting between oral and injectable PrEP in college studentsStrategies to promote PrEP persistence in adolescents Best approaches to address readiness to start PrEP in adolescents (eg, creating nonjudgmental environments, addressing misconceptions)Considerations for local consent lawsAvailable data on PrEP young adolescents (eg, age and weight limits)Initiatives in place to address racial and ethnic disparities associated with PrEP uptake and persistence The role of on-demand PrEP in transgender individuals receiving gender-affirming hormone therapy Offering patient-centered care Educating healthcare professionals on how to prescribe PrEPFaculty: Jill Blumenthal, MD, MAS Associate Professor of MedicineDivision of Infectious Diseases and Global Public HealthDepartment of MedicineUniversity of California, San DiegoSan Diego, CaliforniaKenric B. Ware, PharmD, MBA, AAHIVP Clinical Associate ProfessorDepartment of Pharmacy PracticeMercer University College of PharmacyAtlanta, GeorgiaLink to full program: https://bit.ly/3Fqdgs9 Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this episode, Iskandar Azwa, MBChB, MRCP; Nikos Dedes; Beng Eu, MBBS; Bernadette Sharp; and Jeff Taylor discuss challenges and opportunities with long-acting ART implementation, including:Personal experiences with receiving LA ART Views on long-acting ART in the development pipelinePerspectives on self-administration of LA ARTPresenters:Iskandar Azwa, MBChB, MRCPAssociate ProfessorInfectious DiseasesFaculty of MedicineUniversity of MalayaKuala Lumpur, MalaysiaNikos DedesPositive VoiceAthens, GreeceBeng Eu, MBBSDoctorPrahran Market Clinic Melbourne, Victoria, AustraliaBernadette SharpAdvocateJeff TaylorExecutive DirectorHIV+Aging Research ProjectPalm Springs, CaliforniaContent based on an online CME program supported by an independent educational grant from ViiV Healthcare. ViiV Healthcare was not involved in the development of content or selection of faculty for this educational activity.Link to downloadable slides: https://clinicaloptions.com/CE-CME/infectious-disease/slides-fourth-90-and-la-art/17553-25368 Link to full program: https://bit.ly/3EwEnRJ Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this episode, Raphael J. Landovitz, MD, MSc, and Hyman Scott, MD, MPH, discuss key considerations for PrEP uptake in transgender individuals and racial and ethnic minority men who have sex with men, including: Misconceptions about PrEP eligibility Strategies to improve lab monitoring on PrEP Leveraging patient navigators and clinic staff to expand PrEP accessData on PrEP efficacy in key populations (eg, transgender men, people who inject drugs)Considerations for prescribing on-demand and same-day PrEP Addressing healthcare professional hesitancy to prescribe PrEPUS Preventive Services Task Force PrEP guideline updatesBundling sexually transmitted infection services with PrEPFacultyRaphael J. Landovitz, MD, MScProfessor of MedicineDivision of Infectious DiseasesDavid Geffen School of MedicineUniversity of California, Los AngelesDirector, UCLA Center for Clinical AIDS Co-Director, Center for HIV Identification, Prevention, and Treatment Services Los Angeles, CaliforniaHyman Scott, MDAssistant Clinical ProfessorDepartment of MedicineUniversity of California, San FranciscoClinical Research Medical DirectorBridge HIVSan Francisco Department of Public HealthSan Francisco, CaliforniaLink to full program: https://bit.ly/3PZGYdR Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this episode, Angela Branche, MD, discusses the Advisory Committee on Immunization Practices recommendations for RSV vaccines in older adults, including: Use of shared clinical decision-making How to approach the conversation about the RSV vaccine with patientsKey populations who may benefit the most, such as those at risk for severe RSV disease (eg, increasing age and persons who are frail or have cardiopulmonary comorbidities)Faculty: Angela Branche, MDAssociate Professor of MedicineDivision of Infectious DiseasesDepartment of MedicineUniversity of RochesterRochester, New YorkLink to full program: https://bit.ly/3nb25xeLink to downloadable slides: https://bit.ly/3nb25xe Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this episode, Renslow Sherer, MD, discusses managing virologic failure in a person living with HIV who is heavily treatment experienced, including:Guideline recommendations for selecting a new ART regimenOptions for patients with multidrug-resistant HIV from existing drug classes and novel mechanisms of action with no cross-resistanceData from TMB-301 and TMB-311 for ibalizumab, BRIGHTE for fostemsavir, and CAPELLA for lenacapavir on the use of these agents for people living with HIV who are heavily treatment experienced with multidrug-resistant HIVPresenter:Renslow Sherer, MDDirectorInternational HIV Training CenterProfessor of MedicineSection of Infectious Diseases and Global HealthDepartment of MedicineUniversity of ChicagoChicago, IllinoisTo download the slides:https://bit.ly/3OcqxIETo view the full online program:https://bit.ly/3ZjSFhg Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this episode, Oni Blackstock, MD, MHS, and Brittany Williams, PhD,discuss key considerations to pre-exposure prophylaxis (PrEP) uptake in cisgender women, including: The misconception by patients and healthcare professionals (HCP) that cisgender women are at low risk for HIV Reframing HIV prevention from “risks” to “reasons” such as promoting self-care and taking control of one’s own sexual healthCDC PrEP guidance recommendations Increasing PrEP awareness by sharing PrEP experiences with others in the communityThe importance of community representation in PrEP marketing and campaigns Challenges with finding HCPs who prescribe PrEP for cisgender womenPromoting self-advocacy when seeking care, including HIV prevention Strategies for patients to engage with their HCPs to learn about and obtain PrEP Available resources for PrEP coverage Faculty: Oni Blackstock, MD, MHSFounder & Executive DirectorHealth JusticeNew York, New York Brittany Williams, PhDAssistant Professor of Higher Education and Student Affairs AdministrationDepartment of EducationUniversity of VermontBurlington, Vermont Link to full program: https://bit.ly/3PZGYdR Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this episode, Kyle Molina, PharmD, BCIDP, discusses key considerations for successful implementation of long-acting lipoglycopeptides into clinical practice. Listen as he gives perspectives on:Reasons to consider use of long-acting lipoglycopeptides (eg, poor adherence to oral antibiotics, PICC-related costs and complications)Data supporting and challenging cost effectiveness of long-acting lipoglycopeptides Identifying the target patient populationSelecting the right location to provide long-acting lipoglycopeptides Strategies to maximize institutional impact with key stakeholders (eg, hospital avoidance, reduced ED and hospital length of stay) Key characteristics of available long-acting lipoglycopeptides Addressing logistical challenges, including navigating the reimbursement process Faculty:Kyle Molina, PharmD, BCIDPInfectious Diseases Clinical PharmacistScripps Green HospitalLa Jolla, CaliforniaLink to full program: CCO: https://bit.ly/3J4mg8hProCE: https://bit.ly/3P0vB4E Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this episode, Joseph Ahn, MD, MS, MBA; Christina Delacruz Leyson, MD; and Alice Chan, a person who experienced pregnancy as a person living with chronic hepatitis B, discuss solutions for overcoming barriers to HBV care in people of childbearing potential and their infants, including:HBV screening and vaccination in pregnancyManagement of pregnant people who are HBsAg positiveInfant careBreastfeedingPresenters: Joseph Ahn, MD, MS, MBAProfessor of Medicine, Section ChiefDivision of Gastroenterology and HepatologyOregon Health & Science UniversityPortland, OregonChristina Delacruz Leyson, MDAssociate ProfessorMedical Director, Liver Transplant ProgramProgram Director, Hepatology FellowshipUniversity of KentuckyLexington, KentuckyAlice Chan, person living with chronic hepatitis BLink to downloadable slides:https://bit.ly/3rXLTC7Link to program: https://bit.ly/3L3Kz6l Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.